We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neur... Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). Show more
REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates PR Newswire ROCKVILLE, Md., Nov. 6, 2024 Advancement in Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for...
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., Nov. 4, 2024 ROCKVILLE, Md., Nov. 4, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it...
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights PR Newswire ROCKVILLE, Md., Oct. 30, 2024 ROCKVILLE, Md., Oct...
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 PR Newswire ROCKVILLE, Md., Oct. 21, 2024 97% reduction in...
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting PR Newswire ROCKVILLE, Md., Oct. 18, 2024 ROCKVILLE, Md., Oct. 18, 2024 /PRNewswire/ -- REGENXBIO...
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference PR Newswire ROCKVILLE, Md., Sept. 23, 2024 ROCKVILLE, Md., Sept. 23, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.18 | 12.6745435016 | 9.31 | 12.69 | 8.95 | 967492 | 10.90114465 | CS |
4 | 0.18 | 1.74587778855 | 10.31 | 12.69 | 8.535 | 576536 | 10.1495659 | CS |
12 | -1.49 | -12.4373956594 | 11.98 | 13.48 | 8.535 | 524250 | 10.79874655 | CS |
26 | -5.23 | -33.2697201018 | 15.72 | 16.85 | 8.535 | 537934 | 11.99772289 | CS |
52 | -7.31 | -41.0674157303 | 17.8 | 28.8 | 8.535 | 582948 | 15.46302091 | CS |
156 | -27.41 | -72.3218997361 | 37.9 | 38.235 | 8.535 | 459260 | 20.10208845 | CS |
260 | -27.09 | -72.0862160724 | 37.58 | 54.97 | 8.535 | 440957 | 26.86369308 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions